 |
Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
February 2009
Volume 12, Issue 2
|
Cancer Genomics: Enabling patient-rather than disease-driven research
By Olena Morozova and Marco Marra, PhD, FRSC
It is widely recognized that cancer patients with the same diagnosis often respond differently to the same treatment. While this observation has long been attributed to the individual differences among the patients, genomics tools for the first time shed light on what these differences entail. |
|
Letting The Data Speak For Itself: Scott Cormack discusses why 2008 was a milestone year for OncoGenex
By Shawn Lawrence
In 2003 Biotechnology Focus ran a spotlight on a Canadian cancer drug developer, OncoGenex technologies, which was then a relatively young unknown upstart out of Vancouver, BC. Co-founded by Scott Cormack and Dr. Martin Gleave, the principal inventor behind the company’s product pipeline, the two were just preparing to take the company’s lead product into Phase II. Six years later, now heading into Phase III, OncoGenex Pharmaceuticals Inc. as it is now known, has gone from an unknown entity, to grabbing national headlines with its promising data. |
|
Section 116 Hindering Venture Capital Investment In Canada
By Shawn Lawrence
Converting entrepreneurial ideas into commercial products and successful companies requires a steady flow of venture capital investment. Canadian high growth small and medium-sized enterprises that commercialize research depend on venture capital for growth funding. |
|
Is The Canadian Biotechnology Industry Immune From Global Volatility?
By Ulrich J. Krull
Our Canadian biotechnology industry is far from immune to the ongoing global volatility in the economy, and in fact may be reeling given that this sector has historically required long-term investment for generation of substantial gains. |
